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Abstract 
BACKGROUND: Acanthosis nigricans (AN) is acquired hyperpigmentation of the intertriginous body regions. 
Histologically, AN is characterised by a thickened stratum corneum and a variable amount of acanthosis. Although 
benign and rarely symptomatic, AN may be a red flag for underlying pathologies. 
CASE PRESENTATION: We analysed our patients with AN and could differentiate three different patterns, that 
are illustrated by one case report each. The is the benign AN associated with metabolic syndrome including 
obesity. The second type is the paraneoplastic AN malignancy which is associated with a wider range of 
malignancies. This type may occur before, after or with the clinical appearance of the malignancy. The third type 
is relapsing AN after complete remission. We present a patient who had a malignant AN and was treated 
successfully for his cancer. Years later, however, AN relapsed. In that case in association with the appearance of 
skin tags. Cancer restaging excluded a tumour relapse. His BMI was 31.2 kg/m
2
, and the diagnosis of benign AN 
was confirmed. 
CONCLUSIONS: The diagnosis of AN remains incomplete without screening for metabolic syndrome and/ or 
cancer. The combination of AN and skin tags is more often associated with metabolic syndrome. AN may be 
considered as a red flag for malignancies and the metabolic syndrome. 
 
 
 
 
 
 
 
 
 
 
Introduction 
 
Acanthosis nigricans (AN) is acquired 
hyperpigmentation of the intertriginous body regions 
and sometimes the periareolar skin. Besides the 
colour change, the disease most often remains 
asymptomatically. AN can occur as focal or diffuse 
papillomatous, hyperkeratotic, thickened lesions, 
which are symmetrically distributed. It rarely affects 
mucosa such as oral cavities. 
Histologically, AN is characterised by a 
thickened stratum corneum and a variable amount of 
acanthosis. Horn pseudocysts can occasionally be 
present. The darker colour of AN is likely due to 
hyperkeratosis. A subtly mixed cellular infiltrates may 
be seen [1]. 
AN can develop in children, adolescents and 
adults. In children, the commonly affected body region 
is the neck followed by the axillae [2]. 
The prevalence of AN differs between ethnic 
groups. In the US, among native Americans, the 
prevalence was up to 34.2% followed by African 
Americans, Hispanics and Caucasians [3]. 
The pathogenesis of AN is complex. Elevated 
insulin concentrations result in direct and indirect 
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activation of insulin-like growth factor (IGF)-1 
receptors on suprabasal keratinocytes and fibroblasts. 
Other tyrosine kinase receptors such as epidermal 
growth factor receptor (EGFR) and fibroblast growth 
factor receptor (FGFR) may also contribute to 
hyperproliferation of keratinocytes and fibroblasts [4]. 
However, in obesity, the insulin concentrations are 
lower than warranted for such effects [5]. Extensive 
AN has been associated to hypochondroplasia with 
FGFR3 mutations [6]. Another possible, but the very 
rare association is a mutation of the ELOV1 gene that 
encoded ELOVL fatty acid elongase 1, which 
catalyses elongation of saturated and 
monounsaturated C22-C26-very long-chain fatty acids 
[7]. Malignancy-associated AN might be explained by 
elevated levels of growth factors such as transforming 
growth factor (TGF-α), which can stimulate EGFR [8]. 
What causes the intertriginous areas to be most 
responsive has yet not been discovered. 
 
Differential diagnoses 
AN may resemble other disorders such as 
terra firma forme dermatosis [9], confluent and 
reticulated papillomatosis [10], berloque dermatitis, 
Riehl's melanosis, poikiloderma of Civatte [11]. 
 
 
Case reports 
 
Case 1: A 48-year-old adipose male 
presented with hyperpigmented lesions on the thighs 
and scrotum. His body mass index (BMI) was 36 
kg/m
2
. He suffered from arterial hypertension and 
hyperlipidemia. On examination, we observed diffuse 
brownish hyperpigmentation of thighs and scrotal skin 
with papillomatosis (Figure 1). No treatment was 
warranted. We recommended nutritional counselling. 
The diagnosis of benign AN was confirmed. 
 
Figure 1: Figure 1: Benign AN in an obese man 
 
Case 2: A 39-year-old male presented with a 
relapse of intertriginous AN. His medical history was 
remarkable for kidney cancer in 2012 that was found 
after the first episode of AN and completely removed 
by surgery. The diagnosis of AN malignancy was 
confirmed. Five years later he demonstrated with a 
relapse of AN brownish-blackish hyperpigmentation in 
association with skin tags after complete remission in 
2013 (Figure 2). We performed a computerised 
tomography of the abdomen and laboratory 
investigation that gave no hint of cancer relapse. His 
BMI was 31.2 kg/m
2
. The diagnosis of benign AN was 
confirmed, and surgical excision of the thigh lesions 
was performed. We also recommended nutritional 
counselling. 
 
Figure 2: Relapse of AN after successful kidney cancer treatment 
on the neck (a), groins, scrotum and thighs (b), and axillae (c, d). In 
the axillae, skin tags are seen 
 
Case 3: A 62-year female presented with 
brownish hyperpigmentation of the neck, the back and 
the anal fold was presented by the department of 
oncology (Figure 3). She suffered from 
cholangiocarcinoma with peritoneal metastases and 
was treated by chemotherapy with gemcitabine and 
cisplatin — An developed shortly after tumour 
diagnosis. Malignant AN was confirmed, and anti-
pruritic topical therapy with 5% polidocanol ointment 
was recommended. 
 
Acanthosis nigricans and the metabolic 
syndrome 
The major features of the metabolic syndrome 
are insulin resistance, visceral adiposity, atherogenic 
dyslipidemia and endothelial dysfunction [12]. AN has 
a strong association with overweight in adults, 
adolescents and children. Obesity in adults is defined 
as 30 kg/m², whereas in children and adolescents, 
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overweight is defined as ≥ the 95th percentile of the 
sex-specific BMI-for-age growth chart [13]. In a 
Turkish study on obese adults, 47.3% suffered from 
AN [14]. 
 
Figure 3: Malignant AN in a woman with cholangiocarcinoma 
 
Overweight and obese children with AN 
demonstrate significantly higher levels for uric acid, 
fasting glycemia, insulin, glutamic oxalacetic 
transaminase, and homeostasis model assessment 
index than those without AN [15]. This suggests that 
AN is a marker of increased risk for metabolic 
syndrome in children, but the same has been 
demonstrated for other age groups as well [16]. Here, 
AN often is coexistent with multiple skin tags in 
contrast to malignant AN. Patients with AN showed be 
investigated for other symptoms of the metabolic 
syndrome such as blood pressure (BP), fasting 
lipoprotein profile, fasting glucose, haemoglobin A1C, 
fasting insulin, alanine aminotransferase (ALT), 
hyperlipidemia or hyperuricemia [17]. Women with 
polycystic ovary syndrome (POCS) show an 
increased prevalence of metabolic syndrome, type 2 
diabetes (DM2) and cardiovascular disease. AN can 
be a cutaneous marker for POCS [18]. 
 
Acanthosis nigricans and cancer 
AN is a possible paraneoplasia. 
Paraneoplasia is a disorder related to malignancy. It 
can frequently the first sign of a subjacent malignant 
tumour. Although relatively rare, they need to be 
recognised to make an early diagnosis and improve 
the prognosis of the malignancy [19]. The malignant 
conditions that have been associated with AN are 
tumours of the gastrointestinal tract, gynecologic and 
urogenital tumours among others, although gastric 
cancer is the most common (Table 1). In most cases, 
AN occurs concomitantly (61.3%), however, in 17.6% 
of cases, the lesions occur before the tumour 
detection and in 21% of cases, after the tumour has 
become obvious [20]. In contrast to non-malignant 
AN, mucous membranes, in particular, the oral cavity, 
can be affected. 
 
Table 1: Malignant tumours associated with AN 
Tumour   Reference 
Breast cancer  Levine et al., 2010 [21] 
Cholangiocarcinoma Scully et al., 2001 [22] 
Clear-cell renal carcinoma  Ferraz de Campos et al. 2016 [23] 
Endometrial adenocarcinoma Deen et al., 2017 [24] 
Fallopian tube carcinoma West et al., 2018 [25] 
Gallbladder adenocarcinoma  Ziadi et al., 2009 [26] 
Gastric adenocarcinoma Yu et al., 2017 [27] 
Gastric diffuse B-cell lymphoma Mignogna et al., 2009 [28] 
Gastrointestinal stromal tumor Park et al., 2013 29] 
Hepatocellular carcinoma Antonio et al., 2018 [30] 
Ileocecal adenocarcinoma Gunduz et al., 2013 [31] 
Insulinoma Patra et al., 2016 [32] 
Lung cancer Owen 2016 [33] 
Meningioma Dainichi et al., 2008 [34] 
Mycosis fungoides, Sèzary syndrome  Cheng et al., 2015 [35]; Fahmy et al., 2016 [36] 
Ovarian cancer Singh & Rai 2013 [37] 
Pancreatic adenocarcinoma McGinnes & Greer 2006 [38] 
Prostate cancer Tammaro et al., 2016 [39] 
Rectal adenocarcinoma Marschner & Reinhardt 2011 [40] 
Sarcoma Brantsch & Moehrle 2010 [41] 
 
In conclusion, although AN by itself is most 
often an asymptomatic disease without significant 
impairment, the diagnosis is of great importance to 
identify underlying pathologies. The most important is 
the metabolic syndrome in overweight and obese 
patients of any age. The second is the role of 
malignant AN as an obligate paraneoplasia.  
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